What Should Highlight ACR 2021
EP: 1.Recent Achievements in Psoriatic Arthritis Management
EP: 2.Fitting Biologics into the Psoriatic Arthritis Spectrum
EP: 3.Achieving Individualized Psoriatic Arthritis Care
EP: 4.Most Promising Psoriatic Arthritis
EP: 5.Highlighted Psoriatic Arthritis Sessions at ACR 2020
EP: 6.How Different Psoriatic Arthritis Manifestations Affect Care
EP: 7.The Modern Psoriatic Care Team
EP: 8.The Psoriatic Patient's Role in Improving Care
EP: 9.What Should Highlight ACR 2021
EP: 10.Current Issues in nr-axSpA Diagnostics
EP: 11.Takeaways from Four-Year RAPID-axSpA Data
EP: 12.Takeaways from the 52-Week C-axSpAnd Trial
Christopher T. Ritchlin, MD, MPH: I think we're going to see data on new agents that are in phase 3 trials right now. Of course, one of them is bimekizumab, which is an IL-17 ANF antagonist. Upadacitinib, a JAK-1 antagonist, will have more available data moving forward and will probably come out into the market by—bimekizumab, as well. We're going to have more data on agents that block interleukin-23, which are currently in phase 2 and 3 trials. And I think that we may even have, with the application of newer technologies to understand what's going on in the skin and in the joint, more information on basic mechanisms that are driving these diseases. I think is really going to be extremely important.
I think this is going to be an exciting time in the field of psoriatic disease. So, psoriasis has really moved along in a very swift manner, such that we have outcomes in psoriasis, which are truly unimaginable, as recently as 5 years ago. We're not there yet in psoriatic arthritis, but I think we're gaining the knowledge and the strategies to put us in a good footing to see that happen over the next 5-7 years.
